For generations, Alzheimer's disease has resisted every attempt at cure, in part because researchers have focused on the brain's chemistry while the immune system quietly failed in the background. Now, forty patients across three countries have received an experimental therapy — IBC-Ab002 — designed not to clear amyloid plaques but to restore the brain's own aging defenses, a distinction rooted in decades of work by Israeli neuroscientist Michal Schwartz. The Phase 1 results, published in Nature Medicine, found the treatment safe at every dose and biologically active as designed, offering a sm
Israeli immune therapy shows promise in first Alzheimer's human trial
The immune system actively maintains the brain throughout life
Mark
Why does the immune system matter for the brain? I thought the brain was separate from the immune system.
Mimi
That's the old thinking. Schwartz showed that the immune system actively patrols and repairs the brain throughout life. As we age, that immune function weakens, and the brain becomes inflamed and vulnerable. It's not just about amyloid plaques sitting there—it's about the brain losing its ability to clean up and defend itself.
Mark
So this drug wakes up the immune system?
Mimi
Exactly. It releases a brake on immune cells called the PD-L1 checkpoint. In cancer therapy, releasing this brake helps immune cells attack tumors. Here, it helps immune cells clear aging cells and reduce inflammation in the brain.
Mark
But the trial only tested safety, right? We don't know if it actually helps people remember better.
Mimi
Correct. Phase 1 is just the safety gate. What's encouraging is that the drug did what it was designed to do—it reduced biomarkers of neuronal damage. That's a signal worth following. Phase 2 will tell us whether that translates into preserved cognition.
Mark
Why is this different from the amyloid drugs that are already approved?
Mimi
Amyloid drugs target one piece of the puzzle. This targets the brain's ability to maintain itself. Schwartz's argument is that clearing amyloid alone isn't enough if the immune system can't do its job. You need both—or maybe you need the immune system working first.
Mark
How long until we know if this actually works?
Mimi
Phase 2 trials will take years. But the fact that 40 patients tolerated it well and showed the right biological signals is the first real evidence that this approach is worth pursuing in humans.
The Pulse
- Alzheimer's affects tens of millions worldwide, and despite decades of research, no treatment has yet been able to stop the disease in its tracks.
- The dominant amyloid-targeting approach has yielded only modest benefits and, in some patients, serious side effects — leaving a growing sense in the field that something fundamental may have been overlooked.
- Neuroscientist Michal Schwartz spent years challenging the assumption that the brain operates apart from the immune system, ultimately identifying a specific immune checkpoint pathway as a potential lever against neurodegeneration.
- Her company, ImmunoBrain, engineered IBC-Ab002 to act on that pathway, and a 40-patient trial across the UK, Israel, and the Netherlands found no safety concerns at any dose tested.
- The drug also reduced biomarkers linked to neuronal damage and synaptic loss — signs that its biological activity matched its design — clearing the path toward Phase 2 trials that will test whether it can actually preserve memory and cognition.
For generations, Alzheimer's disease has resisted every attempt at cure, in part because researchers have focused on the brain's chemistry while the immune system quietly failed in the background. Now, forty patients across three countries have received an experimental therapy — IBC-Ab002 — designed not to clear amyloid plaques but to restore the brain's own aging defenses, a distinction rooted in decades of work by Israeli neuroscientist Michal Schwartz. The Phase 1 results, published in Nature Medicine, found the treatment safe at every dose and biologically active as designed, offering a small but meaningful foothold in one of medicine's most stubborn frontiers.
Forty patients with early-stage Alzheimer's disease, enrolled at eleven clinics across the United Kingdom, Israel, and the Netherlands, became the first humans to receive IBC-Ab002 — an experimental antibody therapy that approaches the disease from an unexpected direction. Rather than targeting the amyloid plaques that have dominated Alzheimer's research for decades, the drug attempts to revive the brain's own immune defenses, which weaken naturally with age. The results, published in Nature Medicine, confirmed the treatment was safe at every dose and behaved precisely as its designers had intended.
Alzheimer's remains the most common form of dementia, affecting an estimated 33 to 39 million of the 55 million people worldwide living with the condition. Existing medications can ease symptoms or modestly slow decline, but none can stop the disease. Amyloid-targeting drugs — the field's most recent hope — have shown only limited benefit and carry risks of serious side effects, prompting researchers to ask whether amyloid alone tells the full story.
Michal Schwartz, a neuroscientist at the Weizmann Institute of Science and Israel Prize laureate, spent years making the case that the immune system plays a far more active role in brain health than most neurologists had accepted. Her research showed that immune function actively maintains and repairs the brain throughout life, and that its age-related decline — not amyloid alone — fuels the inflammation and neurodegeneration seen in Alzheimer's. Working in mice, her team demonstrated that releasing specific immune 'brakes,' particularly along the PD-1/PD-L1 checkpoint pathway, could reduce inflammation and ease disease symptoms.
To bring that discovery into the clinic, Schwartz co-founded ImmunoBrain, which engineered IBC-Ab002 as a humanized antibody tailored specifically for Alzheimer's. The Phase 1 trial was designed to establish safety, not efficacy — and it did. Beyond confirming tolerability at all doses, researchers observed reductions in biomarkers associated with neuronal damage and synaptic loss, suggesting the drug's mechanism is active in human patients. Whether that biological activity translates into preserved memory and thinking remains the central question, one that Phase 2 trials will now be designed to answer.
Forty patients with early-stage Alzheimer's disease sat in clinics across the United Kingdom, Israel, and the Netherlands, becoming the first humans to receive an experimental antibody therapy that works in a way most Alzheimer's treatments do not. Rather than attacking the amyloid plaques that have dominated the field for decades, this drug—called IBC-Ab002—aims to wake up the brain's own immune defenses, which naturally weaken as we age. The results, published in Nature Medicine, show the treatment was safe at every dose tested and produced biological changes consistent with its design. It is a small but significant opening in a disease that has resisted cure for generations.
Alzheimer's remains the most common form of dementia, affecting an estimated 33 to 39 million of the 55 million people worldwide living with dementia. Current medications can ease symptoms or modestly slow cognitive decline, but none can stop the disease. The newest drugs target amyloid—those sticky protein clumps in the brain that researchers have long believed drive neurodegeneration. Yet amyloid-targeting drugs have shown only modest benefit, and some patients develop dangerous side effects. This has left researchers asking whether amyloid is the whole story, or whether something else is being missed.
Michal Schwartz, a neuroscientist at the Weizmann Institute of Science and a recipient of the Israel Prize in Life Sciences, has spent years arguing that the brain's immune system matters far more than most neurologists realized. She challenged the old assumption that the brain operates in isolation from immune activity. Instead, she showed that the immune system actively maintains and repairs the brain throughout life. As we age, that immune function declines, and this decline—not amyloid alone—drives inflammation and neurodegeneration. About a decade ago, her team demonstrated in mice that releasing certain immune "brakes" could clear aging cells from the brain, reduce inflammation, and ease disease symptoms. They identified the PD-1/PD-L1 immune checkpoint pathway as the target. The findings were striking, but they existed only in animals.
Schwartz co-founded a company called ImmunoBrain to translate her laboratory work into medicine. The company licensed her technology and engineered IBC-Ab002, a humanized antibody designed to act on the immune mechanism she had identified. Though it targets the same PD-L1 molecule involved in some cancer immunotherapies, this version was built specifically for Alzheimer's. The Phase 1 trial enrolled 40 patients at 11 medical centers and tested the drug's safety and tolerability. Researchers found no safety concerns at any dose. More intriguingly, the drug's activity in patients matched what the engineers had predicted, and it reduced biomarkers associated with neuronal damage and loss of synaptic function—the connections between brain cells.
Phase 1 trials are not designed to prove a drug works; they are designed to prove it does not harm. This trial did that. The safety profile, combined with evidence that the drug reduced damage-related biomarkers, gives researchers reason to move forward. Whether IBC-Ab002 can actually slow or reverse cognitive decline remains unknown. That question will be answered in Phase 2 trials, where larger groups of patients will be followed longer to see whether the immune boost translates into preserved memory and thinking. For now, the result stands as a proof of concept: the immune system's decline may be a lever worth pulling in Alzheimer's disease, and pulling it appears to be safe.
Notable Quotes
The goal of our biological therapy is to restore the immune system's youthful capacity to protect the brain— Michal Schwartz, Weizmann Institute of Science
Want the full story?
Read the original at JNS.org ↗
Health & Medicine